Drugs / AZD6750
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07115043 | Jul 2025 → Oct 2029 expected | cutaneous neuroendocrine carcinoma, gastroesophageal cancer, head and neck squamous cell carcinoma, melanoma +5 | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD6750 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07115043 ↗ |
| Route | Intravenous | “AZD6750 administered intravenously (IV) as a single agent” NCT07115043 ↗ |